This content is in French.
MDR-TB: 9 months to change everything?
24 mars 2025
#Tuberculosis #MDRTB #OralTreatment #Bedaquiline #Efficacy #Safety
Multidrug-resistant tuberculosis (MDR-TB) is a particularly concerning form of TB, defined by resistance to isoniazid and rifampicin—the two cornerstone drugs in standard TB treatment. It causes hundreds of thousands of cases worldwide each year and poses a growing threat to public health, especially in high-burden or resource-limited countries.
Standard treatments for MDR-TB are long, complex, and often poorly tolerated. They typically last 18 to 24 months, involve multiple medications, and frequently include prolonged use of injectable drugs, which are associated with severe side effects. Despite these efforts, treatment success rates remain low—around 60%—and adherence is often compromised due to the treatment burden.
Multidrug-resistant tuberculosis (MDR-TB) is a particularly concerning form of TB, defined by resistance to isoniazid and rifampicin—the two cornerstone drugs in standard TB treatment. It causes hundreds of thousands of cases worldwide each year and poses a growing threat to public health, especially in high-burden or resource-limited countries.
Standard treatments for MDR-TB are long, complex, and often poorly tolerated. They typically last 18 to 24 months, involve multiple medications, and frequently include prolonged use of injectable drugs, which are associated with severe side effects. Despite these efforts, treatment success rates remain low—around 60%—and adherence is often compromised due to the treatment burden.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Jing, W., et al. (2025). New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China. Open forum infectious diseases, 12(2), ofaf020
View the source
